Abstract
There is now little doubt that a proportion of patients with adult acute myelogenous leukaemia will achieve long-term survival and possibly cure with combination chemotherapy. Cytosine arabinoside (araC) is one of the most important drugs used in the treatment of this disease. Despite extensive clinical experience over the past 15 years, the schedule of administration remains controversial. These studies were conducted in an attempt to provide a greater understanding of the effect of both the schedule and route of administration on the clinical pharmacology of araC.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bell R, Rohatiner AZS, Slevin ML, Ford JM, Dhaliwal HS, Henry G, Birkhead BG, Amess JAL, Malpas JS, Lister TA (1982) Short-term therapy for acute myelogenous leukaemia. Br Med J 284: 1221
Canellos GD, Skarin AT, Ervin T, Weinstein H (1979) A chemotherapeutic approach to CNS lymphoma and leukaemia by the systemic administration of high dose of antimetabolites. In: Whitehouse JMA, Kay HEM (eds) CNS complications of malignant disease. pp 142–147
Early AP, Preisler HD, Slocum H, Rustum YM (to be published) A pilot study of high-dose cytosine arabinoside for acute leukaemia and refractory lymphoma. Clinical response and pharmacology. Cancer Res
Finklestein JZ, Scher J, Karon M (1970) Pharmacologic studies of tritiated cytosine arabinoside in children. Cancer Chemother Rep 54: 35–39
Grossman S, Thompson G, Trump D (1981) Cerebrospinal fluid (CSF) flow abnormalities in patients with neoplastic meningitis (NM). Proc Am Soc Clin Oncol 22: 382
Ho DHW, Frei E (1971) Clinical pharmacology of 1-B-D-Arabinofuranosylcytosine. Clin Pharmacol Ther 12: 944–954
Jeffreys DB, Pickup JC, Haw CM, Keen H (1979) Subcutaneous desferrioxamine infusion for haemachromatosis. Lancet II (8156/7): 1364–1365
Karanes C, Wolfe SN, Herzig GP, Phillips GL, Lazarus HM, Herzig RH (1980) High-dose cytosine arabinoside (araC) in the treatment of patients with acute non-lymphocytic leukaemia (ANLL). Blood Abstr 504: 191 a
Piall EM, Aherne GW, Marks VM (1979) A radioimmunoassay for cytosine arabinoside. Br J Cancer 40: 548–556
Pickup JC, Keen H (1980) Continuous subcutaneous insulin infusion: a develo** tool in diabetes research. Diabetologia 18 (1): 1–4
Rai KR, Glidewell O, Weinberg V, Holland JF (1981) Long-term remission in acute myelocytic leukaemia (AML): Report of a multi-institutional co-operative study. Proc Am Soc Clin 22: 481
Rees JKH, Sandler RM, Challener J, Hayhoe FCJ (1977) Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT. Br J Cancer 36: 770–776
Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA (1981) The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. Br J Clin Pharmacol 12:507–510
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Slevin, M.L., Piall, E.M., Aherne, G.W., Johnston, A., Lister, T.A. (1983). The Clinical Pharmacology of Cytosine Arabinoside. In: Neth, R., Gallo, R.C., Greaves, M.F., Moore, M.A.S., Winkler, K. (eds) Modern Trends in Human Leukemia V. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 28. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-68761-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-68761-7_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-11858-9
Online ISBN: 978-3-642-68761-7
eBook Packages: Springer Book Archive